Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment

Psychotic Disorders Clinical Trial

Official title:

Dual Diagnosis Psychosis and Substance Abuse: Short- and Middle-term Changes in Symptomatology After Visiting a Group Education Programme to Reduce Consumption of Cannabis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00783185
• Other study ID #: CRET
• Status: Completed
• Phase: Phase 1
• First received: October 30, 2008
• Last updated: January 11, 2010
• Start date: January 2006
• Est. completion date: January 2010

Study information

• Verified date: October 2008
• Source: University of Konstanz
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

Intention of the study is to examine, if the symptomatology of dual diagnosis patients is less severe after a special indication training for reduction of cannabis consumption in comparison to unspecified trainings.

Point of interest is psychopathology and consumerism.

Description:

Dual diagnosis patients (psychosis and cannabis abuse) account for more clinical admissions than single diagnosis patients.

Cannabis misuse is a known risk factor for recurrence of psychosis.

A specified intervention on the basis of a manual for schizophrenic substance abusers is administered to inpatients in a specialized unit for young schizophrenic patients in a psychiatric hospital.

The control group, same indication (psychotic disorder and cannabis misuse) receives social competence training (specified for schizophrenic patients as well).

Admission to groups is randomly.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: January 2010
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of schizophrenia and disorders with psychotic features

• Misuse of cannabis during 12 months preceding admission to hospital

Exclusion Criteria:

• Not able to attend training twice a week for 45 minutes (concentration, attention, psychotic symptoms, agitation)

• Discharge from hospital before completion of training

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Intervention
• Marijuana Abuse
• Mental Disorders
• Psychotic Disorders

Intervention

Behavioral:
• Cannabis-Consumption-Reduction-Training
8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
• Social competence Training
8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences

Locations

Country	Name	City	State
Germany	University of Konstanz	Konstanz	Baden-Württemberg

Sponsors (1)

Lead Sponsor	Collaborator
University of Konstanz

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PANSS Positive and Negative Symptom Scale		post intervention, six months follow-up	No
Secondary	Urinstatus for cannabinoids		weekly during and post intervention, follow-up	No